The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation

Current Opinion in Pharmacology

Volumn 1, Issue 2, 2001, Pages 159-163

  Girard, Thomas J ^a   Nicholson, Nancy S ^a  

^a PFIZER INC   (United States)

Author keywords

Acute coronary syndromes; Drug Discovery; Heparin; Hirudin; Molecular Medicine; Myocardial infarction; Pharmacology; TF FVIIa; Thrombosis; Tick anticoagulant protein; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; FIBRINOLYTIC AGENT; HELMINTH PROTEIN; MONOCLONAL ANTIBODY; NEMATODE ANTICOAGULANT PROTEIN C2; PHENYLALANYL PHENYLALANYL ARGINYL RECOMBINANT FVIIA; PHENYLALANYL-PHENYLALANYL-ARGINYL-RECOMBINANT FVIIA; PROTEIN; THROMBOPLASTIN; TIFACOGIN;

ACUTE DISEASE; ANIMAL; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ACUTE DISEASE; ANIMAL; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY THROMBOSIS; FACTOR VII; FACTOR VIIA; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; HUMAN; PROTEINS; THROMBOPLASTIN;

EID: 0035321911     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00031-5     Document Type: Review

References (40)

1. Taubman M.B., Fallon J.T., Schecter A.D., Giesen P., Medlowitz M., Fyfe B.S., Marmur J.D., Nemerson Y. Tissue factor in the pathogenesis of Atherosclerosis. Thromb Haemostasis. 78:1997;200-204.
2. Carson S.D. Manifestation of cryptic fibroblast tissue factor occurs at detergent concentrations which dissolve the plasma membrane. Blood Coagl Fibrinolysis. 7:1996;303-313.
3. Giesen P.L., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J.T., Badimon J.J., Himber J., Riederer M.A., Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 96:1999;2311-2315. Initial report that challenges the paradigm of TF being involved only in the initiation of coagulation. Experimental evidence that supports a role for blood borne-TF in the propagation of a thrombus is presented.
4. Rauch U., Bonderman D., Bohrmann B., Badimon J.J., Himber J., Riederer M.A., Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 96:2000;170-175.
5. Soejima H., Ogawa H., Yasue H., Kaikita K., Nishiyama K., Misumi K., Takazoe K., Miyao Y., Yoshimura M., Kugiyama K., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 99:1999;2908-2913. This study evaluated the plasma levels of TF in patients with unstable angina and found them to be elevated.
6. Santucci R.A., Erlich J., Labriola J., Wilson M., Kao K.J., Kickler T.S., Spillert C., Mackman N. Measurement of tissue factor activity in whole blood. Thromb Haemost. 83:2000;445-454.
7. Schecter A.D., Spirn B., Rossikhina M., Giesen P.L., Bogdanov V., Fallon J.T., Fischer E.A., Schnapp L.M., Nemerson Y., Taubman M.B. Release of active tissue factor by human arterial smooth muscle cells. Circ Res. 87:2000;126-132.
8. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol. 68:1991;28B-35B.
9. Zaman A.G., Helft G., Worthley S.G., Badimon J.J. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 149:2000;251-266. A recent review that looks at the mechanisms underlying the development of atherosclerotic plaques, factors leading to plaque rupture and subsequent thromboses and their clinical consequences.
10. Badimon J.J., Lettino M., Toschi V., Fuster V., Berrozpe M., Chesebro J.H., Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 99:1999;1780-1787.
11. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary. Atherosclerosis J Pathol. 188:1999;180-188.
12. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., Haines A.P., Stirling Y., Imeson J.D., Thompson S.G. Haemostatic function and ischaemic heart disease: principal result of the Northwick Park Heart Study. Lancet. 2:1986;533-537.
13. Girelli D., Russo C., Ferraresi P., Olivieri O., Pinotti M., Friso S., Manzato F., Mazzucco A., Bernardi F., Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. New Engl J Med. 343:2000;774-780.
14. Harker L.A., Hanson S.R., Wilcox J.N., Kelly A.B. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemost (suppl). 26:(1):1996;76-82.
15. Golino P., Ragni M., Cirillo P., D'Andrea D., Scognamiglio A., Ravera A., Buono C., Ezban M., Corcione N., Vigorito F., et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circulation Res. 82:1998;39-46.
16. Himber J., Kirchhofer D., Riederer M., Tschopp T.B., Steiner B., Roux S.P. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost. 78:1997;1142-1149.
17. Kelley R.F., Refino C.J., O'Connell M.P., Modi N., Sehl P., Lowe D., Pater C., Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood. 89:1997;3219-3227.
18. Murphy M.K., LaChance R.M., Stillwell L.I., Torr-Brown S.R., Girard T.J. Inhibiting factor VIIa-TF activity effectively prevents thrombosis without bleeding side effects [abstract]. Blood. 90:1997;294a.
19. Girard T.J. Tissue factor pathway inhibitor. Sasahara A.A., Loscalo J. New Therapeutic Agents in Thrombosis and Thrombolysis. 1997;225-260 Marcel Dekker, New York.
20. Taylor F.B. Jr, Chang A., Ruf W., Morrissey J.H., Hinshaw L., Catlett R., Blick K., Edgingtion T.S. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circulation Shock. 33:1991;127-134.
21. Nishida T., Ueno H., Atsuchi N., Kawano R., Asada Y., Nakahara Y., Kamikubo Y., Takeshita A., Yasui H. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res. 84:1999;1446-1452.
22. Zoldhelyi P., McNatt J., Shelat H.S., Yamamoto Y., Chen Z.Q., Willerson J.T. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation. 101:2000;289-295.
23. Holmes D.R., Schwartz R.S., Webster M.W. Coronary restenosis: what have we learned from angiography? J Am Coll Cardiol. 17:1991;14B-22B.
24. Jang Y., Guzman L.A., Lincoff A.M., Gottsauner-Wolf M., Forudi F., Hart C.E., Coutman D.W., Ezban M., Ellis S.G., Topol E.J. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 92:1995;3041-3050.
25. Han X., Girard T.J., Baum P., Abendschein D.R., Broze G.J. Jr. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol. 10:1999;2563-2567.
26. Courtman D.W., Schwartz S.M., Hart C.E. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: extrinsic pathway inhibition eliminates luminal narrowing. Circ Res. 82:1998;996-1006.
27. Golino P., Ragni M., Cirillo P., Scognamiglio A., Ravera A., Buono C., Guarino A., Piro O., Lambiase C., Botticella F., et al. Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circulation Physiol. 278:2000;H1507-H1516. Recombinant FVIIai resulted in a significant reduction in both infarct size and no-reflow area in a rabbit model.
28. Giesen P.L.A., Fyfe B.S., Fallon J.T., Roque M., Mendlowitz M., Rossikhina M., Guha A., Badimon J.J., Nemerson Y., Taubman M.B. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemostasis. 83:2000;622-628.
29. Vlasuk G.P., Bergum P.W., Rote W.E., Ruf W. Mechanistic and pharmacological evaluation of NAPc2, a novel small protein inhibitor of the factor VIIa/tissue factor complex [abstract]. Thrombosis and Haemostasis (Suppl). 77:1997;688.
30. Vlasuk G., Bradbury A., Bergum P., Rote W. Early clinical evaluation of rNAPc2, a novel inhibitor of blood coagulation factor VIIa/tissue factor (FVIIa/TF) [abstract]. J Am Coll Cardiol. 33:1999;255a-256a.
31. Lee A., Agnelli G., Buller H., Ginsberg J., Heit J., Rote W., Vlasuk G., Gent M. A dose-response study of the factor VIIa/tissue factor inhibitor rNAPc in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty [abstract]. Blood. 95:2000;491a.
32. Corvas International Inc., San Diego, CA. Corvas launches second phase II clinical trial for injectable anticoagulant, rNAPc2 [see URL: http://www.corvas.com/press_releases/pr_001128.html ].
33. Report number 204640 (Corvas, Corsevin-M™) Drug Data Report 1994, 16(4):352.
34. Lincoff A.M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: A randomized, double-blinded dose-escalation trial-assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. J Am Coll Cardiol. 36:2000;312-313. The preliminary report of results from a clinical trial in which patients were treated with FVIIai following PTCA. The results supported a trend for efficacy with some increase in minor bleeds. Various levels of heparin were needed and given with the FVIIai.
35. De Jong E., Dekkers P.E.P., Creasey A.A., Hack C.E., Paulson S.K., Karim A., Kesecioglu J., Levi M., van Deventer S.J.H., van der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 95:2000;1124-1129.
36. Creasey A.A. New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis. 3:1999;173-182.
37. Dennis M.S., Elgenbrot C., Skeleton N.J., Ultsch M.H., Santell L., Dwyer M.A., O'Connell M.P., Lazarus R.A. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature. 404:2000;465-470. This article reports on the identification of a novel mechanism for the inhibition of TF/FVIIa activity. An 'exosite' inhibitor peptide that binds near to, but in an area distinct from, the FVIIa active site and disrupts activity is presented.
38. Report number 287612 (Aventis Pharma) Drug Data Report 2000, 22(6):517.
39. Report number 277452 (Roche) Drug Data Report 1999, 21(7):610.
40. Senokuchi K., Ogawa K. Preparation of amidinophenylcarbamoylbiphenyl derivatives and heterocyclic analogue thereof as inhibitors of blood coagulation factor VIIa [abstract 184864n]. Chem Abst. 131:1999;709.